Based on Figures 2 and 4, using CRISPR-Cas9 can lower BCL11A expression, which in turn causes γ-haemoglobin levels to increase. In accordance with Figure 3, y-haemoglobin levels remain elevated for at least 18 months, with long-term utility being unknown. Generally, increased foetal haemoglobin production could significantly reduce the morbidity and mortality of beta-thalassemia by limiting the number of required blood transfusions and reducing complications. Insert a line graph to extrapolate the trend based on the available information for predicting the future.

Question

Based on Figures 2 and 4, using CRISPR-Cas9 can lower BCL11A expression, which in turn causes γ-haemoglobin levels to increase. In accordance with Figure 3, y-haemoglobin levels remain elevated for at least 18 months, with long-term utility being unknown. Generally, increased foetal haemoglobin production could significantly reduce the morbidity and mortality of beta-thalassemia by limiting the number of required blood transfusions and reducing complications. Insert a line graph to extrapolate the trend based on the available information for predicting the future. 
is this all necssary or is there anything i have dlete

GPT 3.5 · Answer

Adding a line graph to extrapolate the trend based on available information can help in predicting the future trend of γ-haemoglobin levels when using CRISPR-Cas9 to lower BCL11A expression. This visualization can illustrate the potential long-term utility of this approach in increasing foetal haemoglobin production and reducing the morbidity and mortality of beta-thalassemia.

Therefore, including a line graph to show the expected trend in γ-haemoglobin levels over time can enhance the understanding of the potential impact of CRISPR-Cas9 in this context. It is relevant and can provide valuable insights into the potential benefits of this approach in the treatment of beta-thalassemia.